Phages are particularly advantageous anti-infectives as they are novel therapeutics, can target antibiotic-resistant bacteria ...
BridgeBio Pharma said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial, ...
This is due to research showing that many cough remedies don't provide much more relief than a placebo, reports the Express.
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...
Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo~71.8% ...
You can take ashwaganda at any time of the day. Depending on why you're taking it, it can help with stress, anxiety, exercise ...
Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company is presenting three posters highlighting pivotal new data ...
Trade partners with roasters across the U.S., making it easy to explore new coffee without committing to just one brand.
If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...
Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback